3H Bio is directing its efforts to help patients to recover from their illness and maintain good physical health, a gift from God.

3H Bio was established as an R&D biotech company aiming to achieve better health and welfare through life science research. Having started as a bio-venture company, 3H Bio is now stepping into the global market. This exciting new phase in our company’s history is based on years of vigorous and aggressive research, an effort that resulted in the discovery of a novel drug with strong beneficial effects in the treatment of obesity and related metabolic diseases. The development of novel, highly effective drugs against metabolic diseases is our company’s main objective, and we are determined to overcome all challenges in this path.

The Company: 3H Bio Co., Ltd.

3H Bio Co., Ltd., founded in 2019, is dedicated to developing innovative therapies for metabolic and cardiovascular diseases. While the company maintains a lean core team of only 10, most of its development work is conducted through established and reputable CROs and CDMOs in the United States, Australia, and South Korea. This model ensures both efficiency and credibility, while providing global partners with confidence in the robustness of our pre-clinical and clinical program. 3HBio is backed by committed investors and is currently advancing with Series B funding to accelerate its pipeline.

MK Choe, CEO, Ph.D.